High dose radiation improves treatment outcome in prostate cancer patients

October 26, 2000

BOSTON, MA - Patients with clinically localized prostate cancer have a better chance of beating the disease with higher doses of radiation, which can be safely and precisely delivered to the tumor with few side effects using three-dimensional conformal radiation therapy. While dose escalation has been shown to improve patient prognosis across all disease stages and risk groups, doctors at Memorial Sloan-Kettering Cancer Center have been able to substantiate the success of the treatment using biopsy results.

In a biopsy, several needles are inserted into the prostate to withdraw cells, which are then examined under a microscope. According to preliminary findings from a study being presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston this week, prostate cancer patients who received higher doses of radiation therapy were more likely to have a negative biopsy, indicating the disease had been controlled or cured. Tumors that received lower doses of radiation were less likely to be eliminated.

The lower doses delivered in the study were the standard prescription for radiation therapy when it began in 1989. As three-dimensional technology proved to be the most precise method to deliver radiation, doctors slowly escalated the dose levels when appropriate. This study used biopsy as a barometer to determine whether dose escalation eliminated the disease in the prostate three years after treatment.

Doctors have traditionally monitored levels of Prostate Specific Antigen (PSA) to test the effectiveness of radiation therapy after prostate cancer patients have completed treatment. However, a rise in a patient's PSA level does not always reveal whether the cancer-cell activity detected is in the prostate or somewhere else in the body. "Biopsy provides very accurate information about local disease specifically in the prostate gland, whereas PSA level gives a more general picture," said Michael Zelefsky, MD, a radiation oncologist with expertise in the treatment of prostate cancer at Memorial Sloan-Kettering Cancer Center and lead author of the study.

The research found that lower radiation dose was the strongest predictor of a positive biopsy, indicating the prostate cancer had not been eliminated. The findings also suggest that higher radiation dose was critical in eradicating the disease, even among patients with aggressive prostate cancers - those patients with high Gleason scores in whom cancer cells are more resistant to radiation and more likely to spread to other areas of the body. In the study, which was conducted between 1989 and 1998, 1,100 patients were treated with varying doses of three-dimensional conformal radiation therapy for clinically localized cancer that had not spread beyond the prostate. Three years after treatment, 63 percent of eligible patients received a prostate biopsy. The incidence of positive biopsy was 54 percent among patients who had the lowest radiation dose in the study, compared with only 10 percent among those who had the highest dose. Overall, the vast majority of patients whose biopsy indicated their cancer was controlled or cured were cancer-free and had normal PSA levels five years after treatment.

"The improved biopsy and PSA results support the effectiveness of higher doses of radiation therapy, which translates into a better chance of eliminating the disease in the prostate," said Steven Leibel, MD, chairman of Radiation Oncology at Memorial Sloan-Kettering and senior author of the study.

The use of hormone therapy with radiation treatment was also shown to be a strong predictor of biopsy outcome. Of the 252 patients evaluated in the study, 33 percent were treated with three months of hormone therapy to shrink the size of the tumor prior to radiation treatment. The findings show that patients who were treated with hormone therapy and three-dimensional conformal radiation therapy were less likely to have a positive biopsy compared to patients treated with radiation therapy alone.

According to the American Cancer Society, 179,000 men in the US will be diagnosed with prostate cancer this year, and 37,000 will die of the disease. It is the second leading cause of cancer deaths (after lung cancer) among American men.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Throughout its long and distinguished history, the Center has played a leadership role in defining the standard of care for patients with cancer.

Memorial Sloan Kettering Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.